EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population

Adam Buckley iD, Sara Suliman, Matthew Allum, Nagi Mohammed, Nader Lessan, Carel W le Roux iD, Mohamed Suliman

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Adam Buckley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Arabs, Hypoglycemic Agents, Glycated Hemoglobin. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Tirzepatide is a glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) dual receptor agonist (RA) that reduces glycated haemoglobin (HbA1c) and weight in patients with type 2 diabetes. We assessed the effectiveness of tirzepatide in real‐world use in an Arab population.

Methods

Review of clinical data from a specialist outpatient diabetes centre; study time points and outcome measures were pre‐specified.

Results

Tirzepatide was initiated in 8945 patients between 24 October 2022 and 31 December 2023. Of these, 3686 individuals reached 40 weeks of follow‐up. At initiation, the mean ± SD age was 54.1 ± 11.5 years, body mass index 34.6 ± 6.0 kg/m 2 and HbA1c 7.3 ± 1.5% (56 ± 17 mmol/mol); 2296 (62%) were switched to tirzepatide from another GLP‐RA and 317 (8.6%) reported previous bariatric surgery. The maximum dose dispensed was ≥12.5 mg/week in 1087, 7.5‐10.0 mg/week in 1688 and 2.5‐5.0 mg/week in 911. The mean 40‐week reduction in HbA1c was 0.6 ± 1.2% (8 ± 13 mmol/mol) and the reduction in weight was 4.5 ± 6.9 kg (4.8 ± 7.3%). GLP‐RA‐naïve patients experienced a significantly greater reduction in HbA1c [1.0 ± 1.3% (11 ± 14 mmol/mol) versus 0.5 ± 1.2% (6 ± 13 mmol/mol), p < .0001] and weight (7.2 ± 8.6 vs. 4.2 ± 6.6 kg, p < .0001) compared with previously exposed individuals. Post‐metabolic bariatric surgery patients lost significantly more weight (7.8 ± 9.4 vs. 4.5 ± 7.0 kg, p < .0001). Improvements in blood pressure, lipid profile, and liver transaminases were noted at 40 weeks. Tirzepatide was well tolerated, with 288 (7.8%) of patients discontinuing treatment because of adverse effects, predominantly gastrointestinal.

Conclusion

In real‐world use, tirzepatide significantly reduced HbA1c levels and weight and was well tolerated. Previous GLP‐RA use was associated with significantly lesser HbA1c and weight reduction, and previous metabolic bariatric surgery was associated with greater weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ArabsHypoglycemic AgentsGlycated HemoglobinHumansMiddle AgedMaleFemaleAdultWeight LossAgedBlood GlucoseTreatment OutcomeRetrospective StudiesGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

glucagon‐like peptide‐1 receptor agonistglycaemic controltirzepatidetype 2 diabetesweight change

Substanzen

Hypoglycemic AgentsGlycated HemoglobinTirzepatideBlood Glucosehemoglobin A1c protein, humanGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Imperial College London Diabetes Centre (ICLDC), Abu Dhabi, UAE.
  • Divisions of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
  • Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.

ORCID-Profile: Adam Buckley, Carel W le Roux

Zitieren

APA

Buckley, A., Suliman, S., Allum, M., Mohammed, N., Lessan, N., le Roux, C. W., & Suliman, M. (2024). Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15680

Vancouver

Buckley A, Suliman S, Allum M, Mohammed N, Lessan N, le Roux CW, et al. Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15680

BibTeX
@article{Buckley2024,
  author = {Buckley, Adam and Suliman, Sara and Allum, Matthew and Mohammed, Nagi and Lessan, Nader and le Roux, Carel W and Suliman, Mohamed},
  title = {Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15680}
}
Kostenlos starten →